The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies.
CA Cancer J Clin
; 72(1): 57-77, 2022 01.
Article
en En
| MEDLINE
| ID: mdl-34714553
ABSTRACT
Oral mucositis (OM) is a common, highly symptomatic complication of cancer therapy that affects patients' function, quality of life, and ability to tolerate treatment. In certain patients with cancer, OM is associated with increased mortality. Research on the management of OM is ongoing. Oral mucosal toxicities are also reported in targeted and immune checkpoint inhibitor therapies. The objective of this article is to present current knowledge about the epidemiology, pathogenesis, assessment, risk prediction, and current and developing intervention strategies for OM and other ulcerative mucosal toxicities caused by both conventional and evolving forms of cancer therapy.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Traumatismos por Radiación
/
Estomatitis
/
Trasplante de Células Madre Hematopoyéticas
/
Úlceras Bucales
/
Neoplasias
/
Antineoplásicos
Tipo de estudio:
Diagnostic_studies
/
Etiology_studies
/
Prevalence_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
CA Cancer J Clin
Año:
2022
Tipo del documento:
Article